Sharen schreef op 28 april 2020 15:07:
Met het oog op de Pharming cijfers op 14 mei geven de rapportages van Novartis, Merck en Pfizer vandaag al een prachtig vooruitzicht hoe pharma-bedrijven ervoor staan : “ All ahead off estimates “
www.cnbc.com/2020/04/28/stocks-making...“ Merck (MRK) – Merck came in 16 cents a share ahead of estimates, with quarterly profit of $1.50 per share. The drugmaker’s revenue also topped Wall Street forecasts. “
“Pfizer (PFE) – The drugmaker earned 80 cents per share for the first quarter, 7 cents a share better than consensus. Revenue also beat forecasts and Pfizer reaffirmed its full-year financial outlook“
“Novartis (NVS) – Novartis reported first-quarter profits and sales that came in above analysts’ estimates, with the drugmaker benefiting from customers stocking up on their prescriptions as the coronavirus outbreak took hold.“
Dus drugmakers hebben zeker geen omzet verloren dit voorjaar, en zelfs extra omzet door ‘stocking up’